Therefore, our current investigation also provides insights to establish a foundation to devise new synthetic lethal strategies by combining CHK1 or PARP1 inhibitors with TOP1 inhibitors to counteract WRN and NF‐κB mediated intrinsic tumor resistance in clinical settings. The gene discussed is PARP1; the disease is neoplasm.